South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determining the best dose for a cancer drug combination in clinical trials.The co ...
Onvansertib targets the PLK1 isoform only (not PLK2 or PLK3), is ... to abrogate several DNA repair pathways and trigger a robust immune response by activating the innate immune response through ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback